These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38312368)

  • 1. Exploring the Relationship between Liver Disease, Bacterial Translocation, and Dysbiosis: Unveiling the Gut-Liver Axis.
    Juanola O; Francés R; Caparrós E
    Visc Med; 2024 Feb; 40(1):12-19. PubMed ID: 38312368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.
    Giannelli V; Di Gregorio V; Iebba V; Giusto M; Schippa S; Merli M; Thalheimer U
    World J Gastroenterol; 2014 Dec; 20(45):16795-810. PubMed ID: 25492994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link?
    Maslennikov R; Ivashkin V; Efremova I; Poluektova E; Shirokova E
    World J Clin Cases; 2021 Nov; 9(31):9320-9332. PubMed ID: 34877269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis.
    Riva A; Gray EH; Azarian S; Zamalloa A; McPhail MJW; Vincent RP; Williams R; Chokshi S; Patel VC; Edwards LA
    JHEP Rep; 2020 Dec; 2(6):100151. PubMed ID: 32838247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.
    Fukui H
    Gut Liver; 2021 Sep; 15(5):666-676. PubMed ID: 33071239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.
    Ponziani FR; Zocco MA; Cerrito L; Gasbarrini A; Pompili M
    Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):641-656. PubMed ID: 29806487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shaping of gut immunity in cirrhosis.
    Muñoz L; Caparrós E; Albillos A; Francés R
    Front Immunol; 2023; 14():1139554. PubMed ID: 37122743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver cirrhosis and complications from the perspective of dysbiosis.
    Nie G; Zhang H; Xie D; Yan J; Li X
    Front Med (Lausanne); 2023; 10():1320015. PubMed ID: 38293307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
    Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
    World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease.
    Augustyn M; Grys I; Kukla M
    Clin Exp Hepatol; 2019 Mar; 5(1):1-10. PubMed ID: 30915401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.